CORCEPT THERAPEUTICS INC (CORT)

Insider Trading Filed: 2026-05-07

Key Insights

Chief Development Officer William Guyer executed a 10b5-1 trading plan adopted in November 2024, selling 20,000 shares at an average price of $51.83 while simultaneously acquiring 20,000 shares at $21.65, suggesting a structured diversification rather than loss of confidence in the company.
The officer holds 170,000 stock options exercisable at $21.65 (expiring September 2031) following this transaction, indicating substantial long-term equity upside potential and alignment with shareholder interests despite the contemporaneous sale.
The filing shows net reduction in direct common stock holdings from 22,231 to 2,231 shares after the sale, though this appears pre-planned via the 10b5-1 arrangement rather than reactive selling, limiting negative sentiment implications.

Insider Trading Filed: 2026-05-05

Key Insights

CEO Joseph K. Belanoff sold 40,000 shares on 05/01/2026 at an average price of $50.10 per share, generating approximately $2 million in proceeds through a pre-established Rule 10b5-1 trading plan adopted in November 2024.
The sale was executed under a Rule 10b5-1 plan, indicating this was a pre-planned transaction rather than opportunistic selling, which reduces concerns about negative insider sentiment regarding the company's near-term outlook.
Despite the sale, Belanoff maintains substantial beneficial ownership of 2,878,326 shares (held indirectly through a revocable living trust), demonstrating continued significant alignment with shareholder interests and confidence in the company.

Quarterly Report Filed: 2026-04-30

Key Insights

The filing is dated April 30, 2026 for Q1 ending March 31, 2026, indicating Corcept is a large accelerated filer with 107.35 million shares outstanding as of April 23, 2026.
The document structure references multiple financial statement sections and fair value measurements across various security types (US Treasury, corporate bonds, commercial paper, money market funds), suggesting a diversified investment portfolio.
Comparative periods are included for Q1 2025 and full year 2024 data, enabling year-over-year analysis of operational and financial metrics, though specific revenue and earnings figures are not visible in the provided excerpt.

Current Report Filed: 2026-04-30

Key Insights

Corcept disclosed Q1 2026 financial results and corporate update via press release on April 30, 2026, indicating the company is actively communicating operational performance to the market.
The filing is a routine quarterly earnings announcement (Items 2.02 and 7.01) with the actual financial details contained in the attached press release (Exhibit 99.1), which is not incorporated into SEC filings per the standard disclosure language.
The 8-K was signed by CFO Atabak Mokari, suggesting normal financial reporting procedures and stability in the company's financial leadership as of the filing date.

Insider Trading Filed: 2026-04-24

Key Insights

Director James N. Wilson acquired 2,000 shares of CORT on 04/22/2026 at $0.00, indicating a gift or internal transfer rather than a market purchase, providing limited insight into insider confidence in valuation.
Wilson's total beneficial ownership across multiple entities (trust, family partnership, and GRATs) amounts to approximately 2.4 million shares, demonstrating substantial long-term commitment and alignment with shareholder interests.
The transaction was executed through a power of attorney by Joseph Douglas Lyon on 04/24/2026, suggesting routine administrative handling rather than a material insider trading decision by Wilson himself.
The use of multiple ownership vehicles including 2025 Grantor Retained Annuity Trusts indicates sophisticated estate planning and wealth transfer strategies typical of significant shareholders.

Insider Trading Filed: 2026-03-27

Key Insights

Insider Joseph K. Belanoff, the CEO, sold 26,198 shares of CORT stock on March 25, 2026 at a weighted average price of $50.0735 per share.
The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Belanoff in November 2024, suggesting planned and systematic selling rather than a one-off transaction.
Belanoff continues to beneficially own 2,918,326 shares of CORT stock, either directly or through a revocable trust, indicating he retains a significant equity stake in the company.

Insider Trading Filed: 2026-03-24

Key Insights

James N. Wilson, a director at Corcept Therapeutics, reported a gift of 4,000 shares of common stock, reducing his direct ownership to 200,000 shares.
Wilson also holds indirect ownership of Corcept shares through the James N. Wilson and Pamela D. Wilson Trust (901,067 shares) and the James and Pamela Wilson Family Partners (200,000 shares).
The transaction suggests Wilson may be taking a more passive role in the company, though his family trusts still maintain significant ownership stakes.

Insider Trading Filed: 2026-03-24

Key Insights

Chief Development Officer William Guyer exercised 11,767 stock options and sold 11,767 shares of Corcept Therapeutics common stock, likely as part of a pre-planned 10b5-1 trading plan.
Guyer continues to hold 2,231 shares directly, as well as unvested restricted stock awards, indicating ongoing alignment with shareholder interests.
The sale price of $36.01 per share represents a significant premium over the $21.65 exercise price of the options, suggesting confidence in the company's stock performance.

Insider Trading Filed: 2026-03-06

Key Insights

The reporting person, William Guyer, exercised 8,233 stock options with an exercise price of $21.65 and immediately sold 8,233 shares at an average price of $35.9949, indicating active insider trading activity.
Guyer also holds 224 shares from unvested restricted stock awards granted in December 2025 and 498 shares from unvested awards granted in March 2026, aligning his interests with the company's long-term performance.
The transactions were made pursuant to a 10b5-1 trading plan, suggesting pre-planned and non-discretionary selling, which may reduce concerns about potential insider information being used.

Insider Trading Filed: 2026-02-26

Key Insights

Insider James N. Wilson exercised 100,000 stock options and transferred 89,364 shares to a trust, indicating potential portfolio rebalancing or liquidity needs.
Wilson maintains significant indirect beneficial ownership of 1,434,532 shares through various trusts and family partnerships, suggesting continued alignment with the company's long-term success.
The net exercise of options, with the reporting person retaining a portion of the shares, could signal confidence in the company's future performance.

Annual Report Filed: 2026-02-24

Key Insights

CORCEPT THERAPEUTICS INC (CORT) reported strong revenue growth, with net sales increasing consistently over the past few years, indicating a healthy demand for the company's products.
The company has maintained robust gross margins, suggesting effective cost management and pricing power, which could contribute to sustainable profitability.
CORT's pipeline of product candidates and ongoing clinical trials indicate a focus on research and development, which may provide opportunities for future growth and diversification.

Current Report Filed: 2026-02-24

Key Insights

Corcept Therapeutics reported its financial results for Q4 2025, providing investors with a corporate update.
The company's press release indicates strong financial performance, potentially signaling continued growth and operational success.
Investors should monitor the company's ongoing business developments and assess the potential impact on future financial and operational results.

Current Report Filed: 2026-02-19

Key Insights

Corcept Therapeutics has prevailed in a patent dispute, as the U.S. Court of Appeals ruled that Teva Pharmaceuticals' generic version of Korlym does not infringe on two of Corcept's key patents.
This decision allows Teva to continue marketing its generic version of Korlym, which could potentially impact Corcept's future revenue and market share for the drug.
Investors should closely monitor the ongoing patent landscape and any potential impact on Corcept's competitive positioning and financial performance.

Insider Trading Filed: 2026-02-13

Key Insights

Sean Maduck, President of Corcept Endocrinology, has been actively engaging in transactions involving Corcept Therapeutics (CORT) shares, including acquisitions and disposals.
Maduck holds shares through various trusts and entities, indicating a significant ownership stake in the company.
The reported transactions, including the granting of restricted stock awards, suggest Maduck has a vested interest in the company's long-term success.

Insider Trading Filed: 2026-02-11

Key Insights

The reporting person, Hazel Hunt, exercised 150,000 stock options at $3.88 per share on 02/09/2026, indicating continued confidence in the company's growth prospects.
Hunt subsequently sold 77,968 shares at $41.31 per share to cover the exercise price and tax withholding, suggesting some profit-taking but retaining a substantial ownership stake of 255,437 shares.
The timing of the option exercise, just prior to the 02/26/2026 expiration date, suggests the reporting person wanted to capitalize on the in-the-money value of the options before they lapsed.

Insider Trading Filed: 2026-02-05

Key Insights

Insider William Guyer, the Chief Development Officer, exercised 20,000 stock options and immediately sold the shares for a profit, indicating potential confidence in the company's future performance.
The stock option exercise and sale were conducted pursuant to a pre-established 10b5-1 trading plan, suggesting a level of planning and strategy behind the transaction.
The sale price of $40.87 per share represents a substantial premium over the $21.65 exercise price, potentially signaling the stock's positive market valuation.

Insider Trading Filed: 2026-01-29

Key Insights

The reporting person, G. Leonard Baker Jr., is a director at Corcept Therapeutics Inc. and has been actively trading the company's stock.
Baker has exercised multiple stock options, acquiring a significant number of Corcept shares over the past year. This suggests he may have a positive outlook on the company's performance.
The reported transactions include the exercise of stock options with varying exercise prices, indicating Baker has been actively managing his position in the company over an extended period.

Current Report Filed: 2026-01-22

Key Insights

Corcept Therapeutics announced that its pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer met its overall survival primary endpoint, a significant clinical milestone.
The positive results from the ROSELLA trial could potentially lead to regulatory approval and commercialization of Corcept's relacorilant combination therapy, expanding the company's product portfolio and revenue opportunities.
Investors should closely monitor future updates on the regulatory progress and commercial launch plans for Corcept's new ovarian cancer treatment, as it could have a substantial impact on the company's financial performance.

Insider Trading Filed: 2026-01-08

Key Insights

William Guyer, the Chief Development Officer of Corcept Therapeutics, exercised 20,000 stock options and immediately sold the resulting shares, suggesting some insider selling activity.
The sale price of $35.18 per share represents a significant premium over the $21.65 exercise price, indicating potential profit-taking by the insider.
The transaction was made pursuant to a 10b5-1 plan, which could indicate a pre-arranged trading strategy and mitigate concerns about potential insider information.

Current Report Filed: 2025-12-31

Key Insights

The FDA has issued a Complete Response Letter regarding Corcept's New Drug Application for relacorilant, a potential treatment for hypertension secondary to hypercortisolism.
This delay in the FDA approval process could impact Corcept's near-term revenue growth and pipeline development timelines.
Investors should closely monitor Corcept's response to the FDA's Complete Response Letter and any updates on the relacorilant development program.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information